I am a healthcare professional

Notice


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.


Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.


By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


Cookies


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.


You can find out more about cookies by browsing our Privacy Policy.

 

For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

ADPD 2026

We will be contributing to topics related to
-
06:30 AM
Duration 60mins Copenhagen, Denmark
Data-driven approaches to representative US enrolment planning in the TRONTIER studies of trontinemab in early symptomatic Alzheimer’s disease
Jessica Colby-Milley, Daniel Gautieri, Michelle Johnson, Kelly Markham-Coultes, Angeliki Thanasopoulou, Frank Perilli, Erin Beck, Ruth Croney
Duration 60mins Copenhagen, Denmark
Explaining AD progression in clinical trials using a multi-modal panel of baseline biomarkers
Roxana Aldea, João A. Abrantes, Orwa Albitar, Paul Delmar, Carsten Hofmann, Luka Kulic, Janice Smith, Antoine Soubret
Duration 48hrs Copenhagen, Denmark
WEARABLE-BASED DETECTION OF SHUFFLING AND TURNING BEHAVIOUR IN PARKINSON'S DISEASE PATIENTS EXPERIENCING FREEZING OF GAIT
Lorenza Angelini
Duration 48hrs Copenhagen, Denmark
VALIDATING A DEVICE-AGNOSTIC ALGORITHM FOR WEARABLE GAIT ASSESSMENT IN PARKINSON'S DISEASE
Lorenza Angelini
Duration 48hrs Copenhagen, Denmark
Differences in Psychological Impact, Burden, and Coping Strategies between Male and Female Informal Caregivers of People with Mild Cognitive Impairment
Elena Garcia-Arcelay
Duration 48hrs Copenhagen, Denmark
Sustained effect of prasinezumab on Parkinson’s disease motor progression in the open-label extension of the PASADENA trial, 5-year update
Fabiana Gullotta
Duration 48hrs Copenhagen, Denmark
Roche Rater Academy: experience-based tailored training maintains clinical dementia rating data quality in Alzheimer’s disease
Krzysztof Smigorski, Enrique Gaspar, Nathalie Pross, Ruth Croney, Peter Deaton, Jennifer Eyerman, Saffra Knox, Douglas Osman, Danielle DiGregorio, Briana Webber-Lind, Kristina Davidsson
Duration 48hrs Copenhagen, Denmark
Evaluating diffusion MRI as a biomarker of treatment response in amyloid-targeting Alzheimer’s Disease trials
Susanna Gobbi, Antonio Cerdán Cerdá, Muhamed Barakovic, Erica Silvestri, Matteo Tonietto, Nicola Spotorno, Gregory Klein, Stefano Magon
Duration 48hrs Copenhagen, Denmark
Evaluation of Elecsys Phospho-Tau (217P) Plasma assay performance across care settings and cognitive statuses for Alzheimer's disease diagnosis
Annunziata Di Domenico, Sayuri Hortsch, Sabrina Jamal, David Caley, Michael Hodsdon, Ming Lu, Marko Knoll
Duration 48hrs Copenhagen, Denmark
Prasinezumab's impact on neuromelanin- and iron-sensitive MRI biomarkers in Parkinson's disease: findings from the PADOVA phase IIB study
Thomas Kustermann, Štefan Holiga, Rayo Akande, Judith Anzures-Cabrera, Nathalie Pross, Annabelle Monnet, Tania Nikolcheva, and Gennaro Pagano
Duration 48hrs Copenhagen, Denmark
Digital Health Technology Detects Group Differences in Practically-Defined OFF-L-DOPA State: Results of PADOVA PH IIb Study of PRASINEZUMAB
Kirsten I Taylor, Stefan Lambrecht, Marzia Scelsi, Nathalie Pross, Annabelle Monnet, Thomas Kustermann, Yulia Gazizova, Florian Lipsmeier, Michael Lindemann, Gennaro Pagano, Werner Popp, Tania Nikolcheva and the PADOVA Investigators and the Prasinezumab Study Group
01:30 PM
Duration 15mins Bella Center Copenhagen, Hall 180-181
Topline results of a Phase 1b study testing an NLRP3 inflammasome inhibitor in early-stage Parkinson’s disease
Gennaro Pagano
12:50 PM
Duration 48hrs Copenhagen, Denmark
Harmonizing amyloid PET tracers at the regional level: evaluation of regional Centiloid equations
Erica Silvestri, Pavanjit Chaggar, Susanna Gobbi, Roxana Aldea, Gregory Klein, Matteo Tonietto
Duration 48hrs Copenhagen, Denmark
Advancing Inclusive Representation in Early-Stage Parkinson's Disease Clinical Trials
Loes Rutten-Jacobs, Adriana Reyes, Nathalie Pross, Bruno Jolain, Emma Hill, Jenee Williams, Denise Coley, R. Bernard Coley, Matthew May, Sola Onilari
02:35 PM
Duration 15mins Bella Center Copenhagen, Hall A3
Modeling PD Progression To Quantify Long-Term Treatment Effects
Ben Ribba
09:10 AM
Duration 15mins Bella Center Copenhagen
Effects of alpha-synuclein co-pathologies on AD progression and gantenerumab efficacy identified by CSF and volumetric MRI signatures
Gregory Klein, Thomas Kusterman, Antonio Napolitano, Daria Rukina, Anton Belousov, Muhamed Barakovic, Duygu Tosun, Luka Kulic, Azad Bonni, Geoffrey A. Kerchner, Gennaro Pagano
10:25 AM
Duration 15mins Hall A3
TRAVELLER master pre-screener study update: Broadening recruitment into TRONTIER 1 and 2, Phase III studies in early symptomatic Alzheimer’s disease
Christopher Lane, Teresa Gleissl, Nicola Voyle, Angeliki Thanasopoulou, Katie Marsh, Derrek Hibar, Alina Bauer, Imke Kirste, Annunziata Di Domenico, Tobias Bittner, Gregory Klein, Ruth Croney, Janice Smith
Duration 15mins Bella Center Copenhagen
Brainshuttle™ transport mechanisms: Impact on amyloid-beta target engagement and vascular distribution
Roberto Villaseñor, Nils O’Brien, Urs Langen, Ann-Katrin Wolf
11:25 AM
Duration 15mins Bella Center Copenhagen, Hall A2
Prasinezumab in Early-Stage Parkinson's Disease: Additional Data from the PADOVA Study
Tania Nikolcheva
01:55 PM
Duration 15mins Hall A3
A Phase I, single ascending dose study investigating an antisense oligonucleotide targeting APOE in individuals with early symptomatic Alzheimer’s disease
Rosanna Tortelli, Agnès Poirier, Krzysztof Smigorski, Eduardo A Aponte, Karolina E. Kolaczynska, Maddalena Marchesi, Nikhat Parkar, Chiara Martinelli, Karolin Rommel, Tracie Carey, Lisa Squassante, Carsten Buerger, Martin Bopst, Hans Peter Grimm, Erich Koller, Lynette Foo, Alexander Stephan
Coming soon